Fusen Pharmaceutical Company Limited (1652.HK)
HKD 0.25
(0.41%)
HKD 0.25
(0.41%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 106.47 Million CNY | 24546.3% |
| 2022 | 432 Thousand CNY | -99.45% |
| 2021 | 77.94 Million CNY | 289.7% |
| 2020 | 20 Million CNY | 0.0% |
| 2019 | 20 Million CNY | -77.78% |
| 2018 | 90 Million CNY | 184.81% |
| 2017 | 31.6 Million CNY | 8.27% |
| 2016 | 29.18 Million CNY | -80.49% |
| 2015 | 149.6 Million CNY | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 107.3 Million CNY | 0.0% |
| 2024 Q1 | 107.3 Million CNY | 1.51% |
| 2023 Q1 | 1.2 Million CNY | 178.01% |
| 2023 FY | 106.47 Million CNY | 24546.3% |
| 2023 Q4 | 106.47 Million CNY | 0.0% |
| 2023 Q3 | 106.47 Million CNY | 8765.28% |
| 2023 Q2 | 1.2 Million CNY | 0.0% |
| 2022 Q3 | 432 Thousand CNY | -99.43% |
| 2022 FY | 432 Thousand CNY | -99.45% |
| 2022 Q2 | 75.39 Million CNY | 0.0% |
| 2022 Q1 | 75.39 Million CNY | -3.27% |
| 2022 Q4 | 432 Thousand CNY | 0.0% |
| 2021 Q1 | 21.29 Million CNY | 6.46% |
| 2021 Q3 | 77.94 Million CNY | 266.07% |
| 2021 Q4 | 77.94 Million CNY | 0.0% |
| 2021 FY | 77.94 Million CNY | 289.7% |
| 2021 Q2 | 21.29 Million CNY | 0.0% |
| 2020 Q1 | 20 Million CNY | 0.0% |
| 2020 FY | 20 Million CNY | 0.0% |
| 2020 Q4 | 20 Million CNY | 0.0% |
| 2020 Q3 | 20 Million CNY | 0.0% |
| 2020 Q2 | 20 Million CNY | 0.0% |
| 2019 Q3 | 20 Million CNY | 0.0% |
| 2019 Q1 | - CNY | -100.0% |
| 2019 Q2 | - CNY | 0.0% |
| 2019 FY | 20 Million CNY | -77.78% |
| 2019 Q4 | 20 Million CNY | 0.0% |
| 2018 Q2 | 90 Million CNY | 0.0% |
| 2018 Q4 | 90 Million CNY | 0.0% |
| 2018 Q3 | 90 Million CNY | 0.0% |
| 2018 FY | 90 Million CNY | 184.81% |
| 2018 Q1 | 90 Million CNY | 184.81% |
| 2017 Q1 | - CNY | -100.0% |
| 2017 Q4 | 31.6 Million CNY | 0.0% |
| 2017 FY | 31.6 Million CNY | 8.27% |
| 2016 Q4 | 29.18 Million CNY | 0.0% |
| 2016 FY | 29.18 Million CNY | -80.49% |
| 2015 FY | 149.6 Million CNY | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 2.07 Million HKD | -5036.134% |
| Grand Pharmaceutical Group Limited | 990.02 Million HKD | 89.246% |
| Extrawell Pharmaceutical Holdings Limited | 117.12 Million HKD | 9.095% |
| Wai Yuen Tong Medicine Holdings Limited | 276.2 Million HKD | 61.451% |
| Qianhai Health Holdings Limited | - HKD | -Infinity% |
| Lee's Pharmaceutical Holdings Limited | 70.63 Million HKD | -50.733% |
| Essex Bio-Technology Limited | 36.05 Million HKD | -195.29% |
| Tongfang Kontafarma Holdings Limited | 12.8 Million HKD | -731.748% |
| PuraPharm Corporation Limited | 81.09 Million HKD | -31.296% |
| SSY Group Limited | 1.94 Billion HKD | 94.533% |
| JBM (Healthcare) Limited | 43.8 Million HKD | -143.087% |
| Jacobson Pharma Corporation Limited | 592.2 Million HKD | 82.021% |
| China Resources Pharmaceutical Group Limited | 16.61 Billion HKD | 99.359% |